Demographic characteristics of elderly Korean patients with plaque psoriasis, and effectiveness and safety of biological agents

Eur J Dermatol. 2024 Apr 1;34(2):211-212. doi: 10.1684/ejd.2024.4644.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adalimumab / adverse effects
  • Adalimumab / therapeutic use
  • Age Factors
  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Etanercept / adverse effects
  • Etanercept / therapeutic use
  • Female
  • Humans
  • Infliximab / adverse effects
  • Infliximab / therapeutic use
  • Male
  • Middle Aged
  • Psoriasis* / drug therapy
  • Republic of Korea / epidemiology
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Adalimumab
  • Antibodies, Monoclonal, Humanized
  • Etanercept
  • Infliximab